“As an investigator of THR-149, I was encouraged to see the results from its clinical phase 1 trial", Pravin Dugel, M.D., says.
In 2019, Oxurion announced positive topline data for the compound THR-149, a highly potent plasma kallikrein inhibitor to treat diabetic macular edema (DME).
Arshad Khanani, M.D., M.A. about the clinical phase 1 data of THR-687.
Oxurion kick-started 2020 with positive topline data from phase 1 clinical trial evaluating THR-687 for treatment of DME.
Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.
Both Oxurion and Prevent Blindness join forces during November to educate the public on risk factors, symptoms, treatment options, and financial assistance resources.
Diabetic eye diseases affect millions of people globally, and still there's a high unmet need in diagnosis and treatment. It's high time to get the message across to risk groups.
This November, in support of Diabetic Eye Disease Awareness Month, Oxurion is partnering with Prevent Blindness and its sight saving efforts.
“The new name comes from combining the words Oxygen and Orion”, explains CEO Patrik De Haes, MD. “Raising oxygen levels in cells plays a key role in helping prevent and reverse ...
PDR and DME are two manifestations of diabetic retinopathy (DR), and in many respects they stem from the same cause, explains professor Alan Stitt.
“In those parts of the world there are many patients who lack access to routine retinal care,” Dr. Agrawal explains. “We aim to provide clinical care by sending retina ...
“There is currently an explosion in R&D activities in the retinal space. Numerous potential new therapies are ready for translation into clinical studies, making this a truly ...